As the United States continues making unprecedented adjustments to its vaccine schedules, a particular individual has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by questioning COVID-19 vaccinations throughout the pandemic and has focused upon alleged fatalities following COVID-19 vaccination in her brief tenure at the FDA.
Public health authorities were set to announce radical revisions to the childhood immunization program earlier this month, synchronizing the US with Denmark’s vaccine program, sources say – a major change that would place the US out of alignment with a large portion of the world with little proof for public health gain. The planned update has been postponed until the next year.
In place of Vinay Prasad, Dr. Høeg is set to address the audience at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the division this year.
Høeg's temporary position could signify a strengthened alliance between the drug and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a greater focus upon rolling back previously authorized immunizations at the FDA.
The new acting director has repeatedly called for ending specific pediatric shot schedules in the US to become more like Denmark, a country with universal health coverage and a citizenry roughly the population of Wisconsin’s.
To date statements, she has kept her attention on vaccination policy – usually the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.
The appointee has no apparent background in pharmaceutical research, approval processes or leadership, which has been customary for past heads of the CBER. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.
“She doesn’t seem to have any of the qualifications” for running the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in managing a large organization. She lacks background in industry regulation.”
Former directors of CBER would “understand regulatory frameworks and the science of drug development”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that former directors who led CBER have had.”
This division has an vast range of responsibilities at the agency, Woodcock stated.
“Many people just focuses on the novel medication approvals, but the generic program clears thousands of generic drugs. There’s a biosimilars program, OTC medication office and other areas, and all of those have to be looked after,” Woodcock noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”
Additionally, a major administrative component to the job, which supervises in excess of 5,000 personnel. “It’s a huge leadership role, if you execute it properly,” the former official said.
In response to inquiries about Høeg’s credentials and whether this assignment indicates more teamwork among FDA leaders on immunizations, a press secretary said that the “concerns rely on inaccurate presumptions”.
“This background is consistent with the functions of her role,” the spokesperson stated, pointing to the months Dr. Høeg spent counseling the agency head on “medication safety and approval science, including computational safety modeling and shot safety tracking”.
As acting director, Dr. Høeg takes over the commissioner’s new expedited review system, a contentious one-day drug-approval program that apparently troubled her former heads. “How are these therapies being selected for this expedited pathway? Who takes the decisions?” Dr. Howard asked. “There’s a lot of confidentiality happening at the FDA right now.”
In general, he remarked, “the FDA appears to be shifting towards laxer regulations of pharmaceuticals, aside from vaccines.”
With immunizations, Høeg has a more established, if problematic, past, critics observe. She released a analysis using unconfirmed volunteer-provided data to determine the frequency of heart inflammation following Covid immunization. She consulted for the Florida surgeon general Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccinations are more dangerous than they are.
Included in her “wish list” for the current administration featured revising rules for new vaccines and discontinuing “unnecessary” immunizations, she said post-election on a online show. At the FDA, Dr. Høeg has according to sources floated the idea of excluding adolescent males from obtaining COVID-19 vaccinations.
“She is an all-around dogmatist who starts off with her conclusions and tailors the evidence to fit the evidence in a highly deceptive, untruthful manner,” Dr. Howard said.
Dr. Høeg joined other skeptics, {like|
A seasoned casino enthusiast and gaming analyst with over a decade of experience in slot machine mechanics and strategies.
